Early-life serum protein profiles associated with bronchopulmonary dysplasia in extremely preterm infants.

Respir ResSep 18, 2026 (epub)
Clinical ResearchPediatricsPulmonologyOpen access

Susanna Klevebro, Mohit B Panwar, Dirk Wackernagel et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial studied early serum protein profiles in 176 extremely preterm infants (<28 weeks gestational age) to identify associations with bronchopulmonary dysplasia (BPD). The analysis revealed that 108 proteins exhibited distinct trajectories in infants with BPD, highlighting potential immune-related mechanisms involved in its pathogenesis.

Key findings

  • 108 out of 538 analyzed proteins showed distinct trajectories in infants with BPD.
  • Lower levels of Secretoglobin family 3A member 1 (SCGB3A1) and higher intercellular adhesion molecule 1 (ICAM-1) were associated with BPD.
  • Novel findings included lower levels of Leukocyte differentiation antigen CD84 in BPD infants.

Why it matters

Understanding the early serum protein profiles associated with BPD can help identify potential biomarkers and therapeutic targets. This knowledge may inform strategies to mitigate inflammation and improve outcomes in extremely preterm infants.

Source

PubMed · PMID 42760543Free full text on PubMed Central

Published in Respir Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.